Pleasanton, CA, United States of America

Shankar Kumar

This inventor holds 32 USPTO granted patents and 3 published patent applications, plus 12 CIPO patents and 16 EPO patents, primarily in Antibody Therapeutics. Top assignees: The University of Texas System, Abbvie Inc., Gene Techno Science Co., Ltd.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shankar Kumar. Retrieved from https://idiyas.com/inventor/shankar-kumar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 32 

% Patents Active = 59.4

 

 

Average Co-Inventor Count = 5.4

ph-index = 10

Forward Citations = 347(Granted Patents)


Location History:

  • Watertown, MA (US) (2007 - 2009)
  • Newton, MA (US) (2009)
  • Pleasonton, CA (US) (2013)
  • Pleasanton, CA (US) (2007 - 2023)

Company Filing History:


Years Active: 2007-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antibody Therapeutics
Anti-OX40
Interleukin-13
Anti-TROP-2
Humanized Antibodies
Cytotoxicity
Nucleic Acid Encoding
Thermoelectric Properties
Nanocrystals
Cancer Treatment
Psoriasis Treatment
Metal-Doped Nanoparticles
32 patents (USPTO):Explore Patents

Title: Unveiling the Innovations of Shankar Kumar

Introduction:

Shankar Kumar, a prolific inventor based in Pleasanton, CA, has made significant contributions to the field of biotechnology and healthcare with 28 patents to his name. His cutting-edge work has been pivotal in advancing methods and compositions for neurological disorders and immunotherapy.

Latest Patents:

1. **Methods and Compositions for the Generation and Use of Humanized Conformation-Specific Phosphorylated Tau Antibodies**: In this patent, Shankar Kumar introduces conformation-specific antibodies designed to bind to and neutralize the activities of phosphorylated-Threonine 231-tau protein (pT231-tau). These antibodies hold promise in treating neurological disorders associated with elevated cis-pT231-tau protein expression.

2. **Interleukin-13 Binding Proteins**: Shankar Kumar's innovation in this patent revolves around IL-13 binding proteins. His work focuses on developing antibodies, including chimeric, CDR grafted, and humanized antibodies with high affinity for hIL-13. These antibodies are adept at neutralizing hIL-13 activity and have applications in detecting and inhibiting hIL-13 activity in disorders where it is detrimental.

Career Highlights:

Having worked at institutions like the University of Texas System and AbbVie Inc., Shankar Kumar has honed his skills in research and development. His expertise in biotechnology and pharmaceuticals has been instrumental in pushing the boundaries of innovation.

Collaborations:

Throughout his career, Shankar Kumar has collaborated with esteemed professionals in the field, including Naoya Tsurushita and J Yun Tso. These collaborations have fostered a culture of innovation, leading to groundbreaking inventions in healthcare and biotechnology.

Conclusion:

In conclusion, Shankar Kumar stands as a beacon of innovation in the realm of biotechnology and healthcare. His patents exemplify his commitment to pushing the boundaries of scientific knowledge and developing solutions that have the potential to impact countless lives.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…